PBM
MRNS

Propel Bio Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Propel Bio Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-180,100
Closed -$1.63M – 32
2024
Q1 		$1.63M Hold
180,100
– – 0.95% 19
2023
Q4 		$1.96M Buy
+180,100
New +$1.35M 1.62% 19

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Propel Bio Management's MRNS Position: Q2 2024 in Review

Propel Bio Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 180,100 shares — an estimated $1.63M sold.

Propel Bio Management first reported a position in MRNS in Q4 2023 and held it in 2 quarters. The position peaked at $1.96M in Q4 2023. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Propel Bio Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Propel Bio Management sold 180,100 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $1.63M.
  • Propel Bio Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2023 and held it in 2 quarters.
  • Propel Bio Management's Marinus Pharmaceuticals, Inc position peaked at $1.96M in Q4 2023.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Propel Bio Management's 13F filing for Q2 2024, filed 12 Aug 2024.